Orris

give answer on diabetes but in points not much explanation. for 15 marks for physiotherapy exams

Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive data from Harrison's, Washington Manual, and Tintinalli's Emergency Medicine. Here is the complete answer structured for a 15-mark physiotherapy exam:

Diabetes Mellitus - 15 Marks (Physiotherapy Exam)

1. Definition

  • Diabetes Mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both.
  • It leads to disturbances in carbohydrate, fat, and protein metabolism.

2. Classification (ADA Criteria)

TypeMechanism
Type 1 DMAutoimmune destruction of pancreatic beta cells → absolute insulin deficiency
Type 2 DMInsulin resistance + progressive beta cell secretory failure
Gestational DMDiabetes diagnosed during pregnancy (not pre-existing)
Other typesMODY, drug-induced (steroids, antipsychotics), cystic fibrosis, pancreatitis
(Source: Harrison's Principles of Internal Medicine 22e, Creasy & Resnik's Maternal-Fetal Medicine)

3. Pathophysiology

Type 1 DM:
  • Autoimmune T-cell mediated destruction of islets of Langerhans
  • Autoantibodies: islet cell antibodies, anti-insulin, anti-GAD65, anti-IA-2
  • Results in absolute insulin deficiency
  • Genetic susceptibility (>60 loci identified) + environmental trigger (enteroviruses)
Type 2 DM:
  • Central defect: insulin resistance (impaired insulin-mediated glucose uptake)
  • Compensatory hyperinsulinemia → progressive beta cell exhaustion
  • Increased hepatic glucose production
  • Obesity is a major contributory factor

4. Clinical Features (Signs & Symptoms)

Classic triad ("3 Ps"):
  • Polyuria - osmotic diuresis due to glycosuria
  • Polydipsia - compensatory increased thirst
  • Polyphagia - cellular starvation despite hyperglycemia
Additional features:
  • Unexplained weight loss
  • Fatigue and weakness
  • Blurred vision (lens changes with glucose fluctuations)
  • Recurrent infections (fungal, UTI, skin)
  • Slow wound healing
  • Numbness/tingling in hands and feet (early neuropathy)

5. Diagnostic Criteria (ADA)

TestPrediabetesDiabetes
Fasting Plasma Glucose100-125 mg/dL≥126 mg/dL
2-hr OGTT (75g)140-199 mg/dL≥200 mg/dL
Random Plasma Glucose-≥200 mg/dL + symptoms
HbA1c5.7-6.4%≥6.5%
  • Diagnosis requires two abnormal tests in asymptomatic patients, or one test + symptoms
  • HbA1c target for treatment: <7%
(Source: Tintinalli's Emergency Medicine, Washington Manual of Medical Therapeutics)

6. Complications

Microvascular (due to direct hyperglycemia damage):

  • Diabetic Retinopathy - leading cause of blindness; microaneurysms, cotton wool spots, proliferative changes
  • Diabetic Nephropathy - leading cause of end-stage renal disease (ESRD); affects 20-40% of diabetics
  • Diabetic Neuropathy - peripheral sensorimotor + autonomic neuropathy; numbness, pain, loss of reflexes

Macrovascular (accelerated atherosclerosis):

  • Coronary artery disease (CAD)
  • Cerebrovascular disease (stroke)
  • Peripheral arterial disease (PAD) - risk for diabetic foot/gangrene

Other complications:

  • Diabetic foot ulcers
  • Autonomic neuropathy (postural hypotension, gastroparesis, neurogenic bladder)
  • Diabetic ketoacidosis (DKA) - Type 1 emergency
  • Hyperosmolar hyperglycemic state (HHS) - Type 2 emergency
(Source: Washington Manual, Robbins Basic Pathology, Goldman-Cecil Medicine)

7. Management

A. Lifestyle Modifications:

  • Diet control: low glycemic index, reduced refined carbs
  • Regular aerobic exercise (150 min/week) - improves insulin sensitivity
  • Weight reduction in Type 2 DM

B. Pharmacological:

  • Type 1 DM: Insulin replacement (basal-bolus regimen) - mandatory
  • Type 2 DM (stepwise):
    • 1st line: Metformin
    • Add-ons: Sulfonylureas, DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors
    • SGLT-2 inhibitors reduce CV death and HF hospitalization
    • GLP-1 agonists reduce MACE (major adverse CV events)
    • Insulin when oral agents fail or in DKA/HHS

C. Targets:

  • HbA1c < 7%
  • Premeal glucose: 80-130 mg/dL
  • Postprandial glucose: <180 mg/dL
  • BP <130/80 mmHg

8. Physiotherapy Relevance

  • Exercise prescription: Aerobic exercise + resistance training improve glycemic control and insulin sensitivity
  • Diabetic neuropathy management: Balance training, sensory re-education, fall prevention
  • Diabetic foot care: Regular assessment, offloading, wound care assistance
  • Post-amputation rehabilitation: Prosthetic training, gait re-education
  • Cardiovascular rehabilitation: Supervised exercise in CAD/peripheral vascular disease
  • Autonomic neuropathy precautions: Monitor BP changes during exercise, watch for hypotension
  • Peripheral arterial disease: Graded walking program for claudication
  • Pre-exercise screening: Check blood glucose before exercise; avoid exercise if glucose <100 mg/dL or >250 mg/dL
  • Patient education: Foot inspection, footwear advice, lifestyle counseling
Key exam tip: For a 15-mark answer, cover - Definition (1), Classification (2), Pathophysiology (3), Clinical features (2), Diagnosis (2), Complications (3), Management (2), and Physiotherapy role (3 marks). This structure ensures full marks.
This is a shared conversation. Sign in to Orris to start your own chat.